RxDoctor Payments Data

Teodulo Perez

Family · Miami, FLNPI 1043817232

Payments from drug & device makers

$6,869in general payments, 2019–2025

Across 303 payments — averaging $22.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$2K
  • AstraZeneca$1K
  • GSK$882
  • Regeneron Healthcare Solutions, Inc.$855
  • Takeda Pharmaceuticals U.S.A., Inc.$416
  • Amgen$413
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$6,78399%
  • Education$861%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,869 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$36,718
Medicare patients
75
Services billed
1,109

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breo ElliptaFluticasone/Vilanterol14$5,594
SymbicortBudesonide/Formoterol Fumarate15$3,585
Arnuity ElliptaFluticasone Furoate13$3,277
Fluticasone Propionate HfaFluticasone Propionate12$2,808
BreynaBudesonide/Formoterol Fumarate16$1,420
Fluticasone Propionate109$1,376
Albuterol Sulfate HfaAlbuterol Sulfate32$537
Hydroxyzine Hcl44$440
Lidocaine-PrilocaineLidocaine/Prilocaine33$416
Azelastine Hcl29$392
Famotidine33$369
Levocetirizine Dihydrochloride54$263
Triamcinolone Acetonide22$201
Montelukast Sodium29$101

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta, Arnuity Ellipta$882$8,87127 claims
AstraZenecaSymbicort$1,421$3,58515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.

Other family in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →